کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5671553 | 1408060 | 2016 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروب شناسی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice](/preview/png/5671553.png)
چکیده انگلیسی
In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48Â weeks with limited success to all-oral single tablet regimens taken for 12Â weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds, virus factors like hepatitis C virus genotype and host factors like presence of cirrhosis, these favorable outcomes can be compromised. This review discusses the recent clinical trials (from phase 3 registration through real-world application), highlighting the different available regimens and their success rates.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Microbiology and Infection - Volume 22, Issue 10, October 2016, Pages 846-852
Journal: Clinical Microbiology and Infection - Volume 22, Issue 10, October 2016, Pages 846-852
نویسندگان
J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman, the European Study Group for Viral Hepatitis (ESGVH) the European Study Group for Viral Hepatitis (ESGVH),